All In Biotech

Drug Trial Radar · NCT02038647

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).

Last checked: Nov 19, 2026Latest source record: Dec 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

May 12, 2014

Primary completion

Jan 3, 2016

Study completion Jul 10, 2017

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Jan 16, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first) when compared with placebo + paclitaxel.

Conditions

  • Small Cell Lung Cancer

Interventions

  • AlisertibDrug

    Alisertib tablets

  • PlaceboDrug

    Placebo matching tablets

  • PaclitaxelDrug

    Paclitaxel intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA GuidelinesTime frame: Every cycle for first 6 months and then every 2 months until disease progression or death or up to data cut-off: 03 January 2016 (approximately 22 months)

Locations

61 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Boca Raton, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Cleveland, Ohio

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Mons, Belgium

  • Site not named

    Roeselare, Belgium

  • Site not named

    Greenfield Park, Canada

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Olomouc, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Grenoble, France

  • Site not named

    Lyon, France

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Pessac, France

  • Site not named

    Rennes, France

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.